Omni Bio Pharmaceutical, Inc. announced that it has received a Notice of Allowance for its first U.S. patent for the composition of matter of its lead recombinant molecule, Fc-AAT. The claims contained in this Notice of Allowance cover full-length AAT nucleic acid constructs that encode polypeptide components of Omni Bio's Fc-AAT recombinant fusion molecule as well as other AAT fusion polypeptides. Similar patent applications covering Omni Bio's lead Fc-AAT molecule remain under review in Europe and Canada.

Patent applications for a series of follow-on Fc-AAT constructs are also pending on a worldwide basis.